The era of first direct-acting antiviral agents: What did we learn?

What did we learn today?

W e learnt that the development of the intestinal microbiota (IM) is extremely complex and a giant puzzle to piece together from adults and children in both developing and developed countries, or more experimentally. Each piece may or may not have future consequences for the IM. However, we are now at the end of the beginning of finishing just one microbiological puzzle. Additionally, we have t...

One Semester of Occupational Therapy Passed Virtually: What Experiences Did We Learn from Covid-19?

One Semester of Occupational Therapy Passed Virtually: What Experiences Did We Learn from Covid-19?  Masoud Gharib 1, Seyed Ali Hosseini 2     1 Assistant Professor, Department of Occupational, Orthopedic Research Center, Mazandaran University of Medical Sciences, Sari, Iran 2 Professor, Department of Occupational Therapy, University of Social Welfare and Rehabilitation Sciences, Tehran...

COMPETITIONS Robot Competitions : What Did We Learn ?

Thalidomide retrospective: what did we learn?

The year 1986 was the 25th anniversary of the recognition that thalidomide is a potent human teratogen, and our president, Lewis Holmes, asked me to organize a symposium at our 26th annual meeting to commemorate that event which, disastrous though it was, provided an immense stimulus to the development of teratology. I was able to gather a panel of speakers all of whom were deeply involved in t...

The Role of Hepatitis C Virus Core Antigen Testing in the Era of Direct Acting Antiviral Therapies: What We Can Learn from the Protease Inhibitors

Direct-acting antiviral (DAA) therapies have revolutionised the treatment of hepatitis C virus (HCV). The financial cost of DAAs however is significant, and first generation protease inhibitors (PIs) also require frequent monitoring of viral RNA levels to guide treatment. In this context, we examined the relevance of HCV antigen testing to evaluate the potential role in monitoring virological r...